Your Yourlocation: Home > Tiotropium bromide(136310-93-5) is effective in the treatment of early COPD

Dr. Zhong Nanshan introduced the first international Tie - COPD study on clinical interventions for patients with early - stage asymptomatic chronic obstructive pulmonary disease. After two years of treatment with tiotropium bromide(136310-93-5), preliminary results showed that tiotropium significantly improved slow - (FEV1) trough, peak, and forced vital capacity (FVC) in patients with early-stage lung disease, decreased annual FEV1 peak annual decline, sustained improvement in patients with chronic obstructive pulmonary disease (CAT) score, acute exacerbation of chronic obstructive pulmonary disease AECOPD) occurred at a lower risk, and its safety and placebo equivalent, suggesting that tiotropium in the treatment of early COPD effective.

For symptomatic and high-risk patients with chronic obstructive pulmonary disease, often due to disease control does not lead to repeated exacerbation of acute exacerbations and even hospitalization, and optimize drug selection, for the prevention of acute exacerbation is essential. The anticholinergic pathway is an important pathogenesis of chronic obstructive pulmonary disease. The long-acting anticholinergic drug, Sertoli® tiotropium bromide(136310-93-5) bromide, selectively blocks M1, M3 receptors, marked COPD symptoms, reduces acute exacerbation risk. More than 200 clinical trials have demonstrated the role of tiotropium in the treatment of COPD.

The four-year UPLIFT study showed that tiotropium bromide(136310-93-5) was effective in preventing acute exacerbations in patients with severe COPD, significantly reducing the risk of acute exacerbation by 14%, improving lung function and quality of life, and reducing cardiovascular and respiratory adverse events risks.

Address: TEL:0531-82375879 Tiotropium Bromide
© Copyright(C)2014 JINAN DEXINJIA BIO & TECH CO., LTD All Rights Reserved